SANTHE is a Pan-African network of multidisciplinary experts collaborating – through pioneering basic, clinical, and translational research - to empower African scientists in the fight against HIV/AIDS and TB, associated morbidities, and emerging diseases like COVID-19.
SANTHE is a productive African-led scientific consortium which has a strong research and governance infrastructure in support of all partner institutions’ pursuit of intellectual and financial independence.
Only fill in if you are not human
Home Fellowship Page 2
Determining human immunodeficiency virus type 1 (HIV-1) recent infection can help guide prevention and treatment options for newly HIV-1 diagnosed individuals, as well as help guide new approaches to HIV-1 vaccine design. Although Botswana has a high rate of antiretroviral…
Despite the availability of effective anti-retroviral drugs and several HIV preventative methods, the prevalence of HIV remains very high, especially in Sub-Saharan Africa. This makes the development of a protective HIV vaccine a necessity. For the HIV vaccine to be…
Mumba-Mwangelwa’s research question is, “Will the prevailing COVID-19 pandemic have an impact on safety and immunogenicity endpoints in an ongoing phase 1 HIV vaccine trial (HIV CORE 006)? HIV CORE 006, is a phase 1 HIV vaccine trial that aims…
Mwelwa’s project intends to characterise acquired HIV-1 drug resistance mutations that could impact antiretroviral treatment (ART) and limit the efficacy of prevailing drug regimens in ART naive acute infection. She and her team intend to examine drug driven resistance patterns…
Chivaura-Mudukuti’s research project will focus on evaluating antibody responses in three cohorts. These cohorts include anti-retroviral therapy (ART) naive HIV infected long term non-progressors and patients with advanced disease to evaluate antibodies in each cohort. It will also include a…
The development of an effective HIV vaccine has been hindered mainly due to the ability of the virus to evolve and escape the host’s defence system. However, the discovery and analysis of highly networked epitopes (regions/parts) of the virus has…
Despite more than three decades of research, a protective vaccine against HIV-1 group M (HIV-1M) remains elusive. To date, none of the vaccine candidates tested has been able to induce effective humoral immunity. Nevertheless, neutralising antibodies (nAbs) in the broad…
Aurélie Kifack Zetang’s project focusses on the molecular epidemiology of non-M HIV-1 variants and dual M+O HIV-1 infections in HIV-positive patients in Cameroon. HIV-1 is very diverse and this high genetic diversity has an impact on the diagnosis, treatment and…
Despite the success of antiretroviral therapy (ART) in managing clinical disease and preventing viral transmission, there is still no vaccine or cure for HIV. The persistence of virus-infected human cells that remain dormant during ART, poses a significant barrier to…
Maseema and his team aim to uncover immune correlates of protection in subclinical Mycobacterial tuberculosis (Mtb) infection and TB disease. The majority of individuals who are exposed to Mtb infection successfully contain the infection whereby only an immunological memory remains…
